Alzheimer Disease: Cognizance and Potential Aspect of Disease Pathophysiology & Recently Developed Therapeutic Drug Strategies
Abstract
Alzheimer’s disease (AD) is a multifactorial neuron-degenerative old age disease which has no cure. AD causes degeneration of the neuronal cells in the brain which is the main reason of dementia, characterized by a decline in the thinking and independence in daily routine activities. In most of the cases, AD is suspected to be caused by a combination of genetic, lifestyle and environmental factors, affecting the brain over time. The currently approved therapy, which includes cholinesterase inhibitors, NMDA-receptor antagonists and their combinations provides only temporary symptomatic relief. Nowadays, the clinical research is targeting on understanding of Alzheimer pathology1. These are targeting the abnormal tau protein metabolism, removal of beta-amyloid, inflammatory response, cholinergic neuron and free radical damage treatments which can either that stop or modify the course of Alzheimer. Global efforts are continued to identify new targets to develop novel therapeutic agents for the treatment of AD.
Keywords: Alzheimer disease, Dementia, Drug therapy, Drug effect, Amyloid, Amyloid precursor protein, Tau proteins, Acetyl cholinesterase enzyme
Keywords:
Alzheimer disease, Dementia, Drug therapy, Drug effect, Amyloid, Amyloid precursor protein, Tau proteins, Acetyl cholinesterase enzymeDOI
https://doi.org/10.22270/jddt.v14i9.6790References
Briggs R, Kennelly SP, O'Neill D. Drug treatments in Alzheimer's disease. Clinical Medicine. 2016;16(3):247-53. https://doi.org/10.7861/clinmedicine.16-3-247
Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM. Combination drug therapy for the management of Alzheimer's disease. International Journal of Molecular Sciences. 2020;21(9):3272. https://doi.org/10.3390/ijms21093272
Tifratene K, Duff FL, Pradier C, Quetel J, Lafay P, Schück S, Benzenine E, Quantin C, Robert P, participating centres. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). pharmacoepidemiology and drug safety. 2012;21(9):1005-12. https://doi.org/10.1002/pds.3303
Ladner CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergi hypothesis revisited. Journal of neuropathology and experimental neurology. 1998;57(8):719. https://doi.org/10.1097/00005072-199808000-00001
Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimer's & Dementia. 2011;7(6):579-92. https://doi.org/10.1016/j.jalz.2011.02.009
Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs & aging. 2007; 24:155-67. https://doi.org/10.2165/00002512-200724020-00007
Tifratene K, Duff FL, Pradier C, Quetel J, Lafay P, Schück S, Benzenine E, Quantin C, Robert P, participating centres. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). pharmacoepidemiology and drug safety. 2012;21(9):1005 https://doi.org/10.1002/pds.3303
Cacabelos R, Alvarez A, Lombardi V, Fernández-Novoa L, Corzo L, Pérez P, Laredo M, Pichel V, Hernández A, Varela M, Figueroa J. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs of Today (Barcelona, Spain: 1998). 2022;36(7):415-99. https://doi.org/10.1358/dot.2000.36.7.589153
Abou Baker DH, Ibrahim BM, Hassan NS, Yousuf AF, El Gengaihi S. Exploiting Citrus aurantium seeds and their secondary metabolites in the management of Alzheimer disease. Toxicology reports. 2020;7:723-9. https://doi.org/10.1016/j.toxrep.2020.06.001
Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. Journal of Alzheimer's Disease. 2004;6(s6):S61-74. https://doi.org/10.3233/JAD-2004-6S610
Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clinical pharmacokinetics. 2013;52:225-41. https://doi.org/10.1007/s40262-013-0038-9
Ballatore C, Brunden KR, Huryn DM, Trojanowski JQ, Lee VM, Smith III AB. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug design, development and therapy. 2016:3267-79. https://doi.org/10.2147/DDDT.S86463
Tifratene K, Duff FL, Pradier C, Quetel J, Lafay P, Schück S, Benzenine E, Quantin C, Robert P, participating centres. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). pharmacoepidemiology and drug safety. 2012;21(9):1005 https://doi.org/10.1002/pds.3303
Ladner CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergi hypothesis revisited. Journal of neuropathology and experimental neurology. 1998;57(8):719. https://doi.org/10.1097/00005072-199808000-00001
Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs & aging. 2007;24:155-67. https://doi.org/10.2165/00002512-200724020-00007
Breijyeh, Z., & Karaman, R. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules, 2020;25(24):5789. https://doi.org/10.3390/molecules25245789
Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Vergallo A, Farlow MR, Snyder PJ, Giacobini E, Khachaturian ZS, Cholinergic System Working Group, and for the Alzheimer Precision Medicine Initiative (APMI). Revisiting the cholinergic hypothesis in Alzheimer's disease: emerging evidence from translational and clinical research. The journal of prevention of Alzheimer's disease. 2019;6:2-15. https://doi.org/10.14283/jpad.2018.43
Leko MB, Hof PR, Šimić G. Alterations and interactions of subcortical modulatory systems in Alzheimer's disease. Progress in brain research. 2021;261:379-421. https://doi.org/10.1016/bs.pbr.2020.07.016
Leko MB, Hof PR, Šimić G. Alterations and interactions of subcortical modulatory systems in Alzheimer's disease. Progress in brain research. 2021;261:379-421. https://doi.org/10.1016/bs.pbr.2020.07.016
Melzer D. New drug treatment for Alzheimer's disease: lessons for healthcare policy. BMJ. 1998 Mar 7;316(7133):762-4. https://doi.org/10.1136/bmj.316.7133.762
Srivastava S, Ahmad R, Khare SK. Alzheimer's disease and its treatment by different approaches: A review. European Journal of Medicinal Chemistry. 2021;216:113320. https://doi.org/10.1016/j.ejmech.2021.113320
Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genetics in Medicine. 2016;18(5):421-30. https://doi.org/10.1038/gim.2015.117
Fericean RM, Rosca O, Citu C, Manolescu D, Bloanca V, Toma AO, Boeriu E, Dumitru C, Ravulapalli M, Barbos V, Oancea C. COVID-19 clinical features and outcomes in elderly patients during six pandemic waves. Journal of Clinical Medicine. 2022;11(22):6803. https://doi.org/10.3390/jcm11226803
Yang, X., & Huang, S. Sleep deprivation: A risk factor for the pathogenesis and progression of Alzheimer's disease. Heliyon. 2024.
Spoleti, E., La Barbera, L., Cauzzi, E., De Paolis, M. L., Saba, L., Marino, R., ... & D'Amelio, M. Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer's Disease. Molecular Psychiatry, 2024;1-16. https://doi.org/10.1038/s41380-024-02408-9
Published
Abstract Display: 115 
PDF Downloads: 160 PDF Downloads: 50 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.